
Chad Messer
Stock Analyst at Lake Street
(0.11)
# 4,826
Out of 5,162 analysts
483
Total ratings
33.1%
Success rate
-6.3%
Average return
Main Sectors:
Stocks Rated by Chad Messer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Initiated Coverage: Buy | $11 | $2.44 | +350.82% | 1 | Oct 28, 2026 | |
| ONCY Oncolytics Biotech | Reiterated: Buy | $5 | $0.3906 | +1,180.08% | 19 | Oct 14, 2026 | |
| CGEN Compugen | Reiterated: Buy | $6 | $1.88 | +219.15% | 5 | Oct 6, 2026 | |
| COYA Coya Therapeutics | Reiterated: Buy | $17 | $2.98 | +470.47% | 15 | Oct 6, 2026 | |
| CNSY Cerenome | Reiterated: Buy | $50 → $31 | $0.7024 | +4,313.44% | 7 | Oct 1, 2026 | |
| OSTX OS Therapies | Reiterated: Buy | $13 | $0.8204 | +1,484.59% | 20 | Sep 9, 2026 | |
| GNLX Genelux | Reiterated: Buy | $16 | $2.28 | +601.75% | 6 | Jun 30, 2026 | |
| MNPR Monopar Therapeutics | Reiterated: Buy | $103 | $70.29 | +46.54% | 7 | Jun 30, 2026 | |
| KZIA Kazia Therapeutics | Initiated Coverage: Buy | $32 | $5.37 | +495.90% | 1 | Jun 11, 2026 | |
| IMNM Immunome | Reiterated: Buy | $30 | $16.61 | +80.61% | 9 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $0.2839 | +8,705.92% | 13 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $5.06 | +1,382.21% | 6 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.31 | - | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $5.89 | n/a | 18 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $3 | $0.913 | n/a | 17 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $5.08 | n/a | 7 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 | $4.55 | n/a | 5 | Aug 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.0001 | n/a | 11 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $50 | $56.31 | n/a | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $48 | $51.46 | n/a | 31 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $6.78 | n/a | 13 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.4223 | n/a | 17 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $21 | $0.9796 | n/a | 17 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $97.63 | n/a | 19 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $84 | $27.22 | n/a | 50 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $58.26 | n/a | 25 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $6 | $0.00001 | n/a | 17 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $48 | $13.60 | n/a | 6 | Jul 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $30 | $65.83 | n/a | 22 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 → $83 | $0.8798 | n/a | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $166 | $14.17 | n/a | 50 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.275 | n/a | 2 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.76 | n/a | 21 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.12 | n/a | 3 | Nov 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $27 | $10.57 | n/a | 3 | Apr 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $7 | $0.000001 | n/a | 5 | May 7, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $4 | $14.86 | n/a | 6 | Mar 6, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $0.7328 | n/a | 1 | Jan 5, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $0.9698 | n/a | 1 | May 22, 2012 |
C4 Therapeutics
Oct 28, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $2.44
Upside: +350.82%
Oncolytics Biotech
Oct 14, 2026
Reiterated: Buy
Price Target: $5
Current: $0.3906
Upside: +1,180.08%
Compugen
Oct 6, 2026
Reiterated: Buy
Price Target: $6
Current: $1.88
Upside: +219.15%
Coya Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: $17
Current: $2.98
Upside: +470.47%
Cerenome
Oct 1, 2026
Reiterated: Buy
Price Target: $50 → $31
Current: $0.7024
Upside: +4,313.44%
OS Therapies
Sep 9, 2026
Reiterated: Buy
Price Target: $13
Current: $0.8204
Upside: +1,484.59%
Genelux
Jun 30, 2026
Reiterated: Buy
Price Target: $16
Current: $2.28
Upside: +601.75%
Monopar Therapeutics
Jun 30, 2026
Reiterated: Buy
Price Target: $103
Current: $70.29
Upside: +46.54%
Kazia Therapeutics
Jun 11, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $5.37
Upside: +495.90%
Immunome
Jun 1, 2026
Reiterated: Buy
Price Target: $30
Current: $16.61
Upside: +80.61%
May 18, 2026
Reiterated: Buy
Price Target: $25
Current: $0.2839
Upside: +8,705.92%
May 13, 2026
Reiterated: Buy
Price Target: $75
Current: $5.06
Upside: +1,382.21%
Apr 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.31
Upside: -
Nov 1, 2021
Reiterated: Buy
Price Target: $6 → $7
Current: $5.89
Upside: n/a
Aug 17, 2021
Rated: Buy
Price Target: $3
Current: $0.913
Upside: n/a
Aug 13, 2021
Reiterated: Buy
Price Target: $29
Current: $5.08
Upside: n/a
Aug 12, 2021
Reiterated: Buy
Price Target: $49
Current: $4.55
Upside: n/a
Aug 10, 2021
Reiterated: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Aug 10, 2021
Rated: Buy
Price Target: $50
Current: $56.31
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $48
Current: $51.46
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $30
Current: $6.78
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $10
Current: $0.4223
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $21
Current: $0.9796
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $12
Current: $97.63
Upside: n/a
Aug 4, 2021
Rated: Buy
Price Target: $84
Current: $27.22
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $58.26
Upside: n/a
Jul 29, 2021
Rated: Buy
Price Target: $6
Current: $0.00001
Upside: n/a
Jul 15, 2021
Rated: Buy
Price Target: $48
Current: $13.60
Upside: n/a
Jun 28, 2021
Reiterated: Buy
Price Target: $33 → $30
Current: $65.83
Upside: n/a
Jun 7, 2021
Reiterated: Buy
Price Target: $75 → $83
Current: $0.8798
Upside: n/a
May 18, 2021
Reiterated: Buy
Price Target: $166
Current: $14.17
Upside: n/a
May 14, 2021
Rated: Buy
Price Target: $10
Current: $0.275
Upside: n/a
May 10, 2021
Rated: Hold
Price Target: n/a
Current: $28.76
Upside: n/a
Nov 8, 2019
Rated: Hold
Price Target: n/a
Current: $3.12
Upside: n/a
Apr 12, 2018
Reiterated: Buy
Price Target: $30 → $27
Current: $10.57
Upside: n/a
May 7, 2015
Reiterated: Buy
Price Target: $10 → $7
Current: $0.000001
Upside: n/a
Mar 6, 2015
Reiterated: Buy
Price Target: $7 → $4
Current: $14.86
Upside: n/a
Jan 5, 2015
Initiated Coverage: Buy
Price Target: $17
Current: $0.7328
Upside: n/a
May 22, 2012
Initiated Coverage: Buy
Price Target: $5
Current: $0.9698
Upside: n/a